President Trump said he was likely to impose tariffs on pharmaceuticals as soon as the end of the month, starting with a "low ...

In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...

Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...

Childhood vaccines lay the foundation for lifelong health, protecting against diseases like measles, mumps, rubella, and ...

This stock used to be a highflyer but has struggled in recent years as demand waned for its flagship product. Though Moderna ...

The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.

If I have sounded like a broken record these past months, it is because these developments in American public health are as ...

The mass layoffs of federal employees have been unprecedented, devastating, and chaotic but it is the cuts to HHS that are ...

Novavax's growth relies on Sanofi royalties and COVID/flu vaccines, lacking innovation and clear catalysts. Click here to ...

The FDA this week fully approved Moderna’s COVID-19 vaccine for children aged 6 months to 11 years but limited the approval ...

DOJ filed the statement of interest in United States District Court for the case Children’s Health Defense et al. v. Washington Post et al., which lists among its defendants the BBC, Reuters, the ...